Table 1.
The role of PLCε in the different tumor entities.
| Oncogene | Tumor suppressor | ||||
|---|---|---|---|---|---|
| Tumor entity | Model | Ref | Tumor entity | Model | Ref |
| Gastric cancer | Gastric cancer tissue samples from Chinese patients (N=2766) and healthy controls (N=11013) | [30] | Colorectal cancer | Transcriptome datasets from colorectal cancer samples (N=137) and normal mucosa (N=10) | [46] |
| Gastric cancer tissue samples from Chinese patients (N=1059) and healthy controls (N=1240) | [43] | ||||
| Meta-analysis where gastric and esophageal cancer cases (N=8281) and healthy controls (N=10532) were compared | [44] | ||||
| Gastric cancer cell lines AGS, SGC7901, MGC803; tissue samples from patients with gastric cancer (N=74), tissue samples from patients with chronic atrophic gastritis (N=799) | [41] | Colorectal cancer tissue samples obtained from patients and their pair-matched normal tissues (N=50) | [47] | ||
| Meta-analysis where gastric and esophageal cancer cases (N=761) and healthy controls (N=457) were compared | [27] | ||||
| Tissue samples from gastric cancer patients (N=940) | [40] | ||||
| Tissue samples from patients with gastric cancer (N=108) and healthy controls (N=195) from Kashmir Valley | [32] | ||||
| Tissue samples from Korean patients with gastric cancer (N=3245) | [45] | ||||
| Esophageal cancer | ESCC tissue samples (N=222) and controls (N=326); Eca109, TE-1, KYSE-150, KYSE-450 human ESCC cell lines | [27, 39] | Skin cancer | Transgenic PLCε-/- mice developed by authors | [19] |
| ESCC cell lines EC109 and EC9706, | [38] | ||||
| Tissue samples from ESCC patients and pair-matched controls (N=132) | [37] | ||||
| Tissue samples from patients with ESCC (N=135) and age and gender matched controls (N=195) | [32] | ||||
| Tissue samples obtained from patients with ESCC and their age and gender-matched controls (N=550) | [34] | ||||
| GWAS performed on ESCC patients (N=1077) and healthy controls (N=1733), and then repetition of 18 promising SNP on additional number of ESCC patients (N=7673) and healthy controls (N=11013) | [30] | ||||
| Colorectal cancer (rs2274223A >G transition) | Colorectal cancer samples obtained from patients (N=203) and normal tissue samples (N=296); | [48] | Lung cancer | Tissue samples obtained from patients with lung adenocarcinoma - microarray data from Oncomine database | [26] |
| tSNPs in PLCε gene analyzed in colorectal cancer samples from European patients (N=192) and non-cancerous tissues (N=382) | [49] | ||||
| Head and neck cancer | Human oral squamous cell carcinoma HSC-3 cell line | [54] | |||
| Tissue samples from patients with HNSCC (N=1098) and normal tissue (N=1090) | [53] | ||||
| Lung (NSCLC cells) | NSCLC cells obtained from patients with lung cancer (N=36) | [25] | |||
| Transgenic PLCε-/- mice developed by authors | [19] | ||||
| Bladder cancer | Xenograft tumors obtained from cells with knockdown of PLCε; human bladder cancer cell lines BIU-87 | [57] | |||
| Human bladder cancer cell line BIU-87 | [56] | ||||
| Human bladder cancer cell line T24 | [55] | ||||
| Bladder cancer cell lines BIU-87, T24; bladder carcinoma tissue samples (N=48) and adjacent normal tissue (N=21) | [58] | ||||
| Gallbladder cancer | Gallbladder tissue samples from patients (N=416) and controls (N=225) | [59] | |||
| Prostate cancer | Prostate cancer tissue samples (N=37) and benign prostatic hyperplasia (N=10) | [60] | |||
| Skin cancer | Transgenic PLCε-/- mice developed by authors | [22] | |||
| [23] | |||||
| Intestine cancer | Transgenic mouse model of intestine cancer (Min-/-PLCε-/-, Min-/- PLCε+/+) | [24] | |||